Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma.
نویسندگان
چکیده
Between July 2003 and March 2004, nine patients with pretreated mycosis fungoides were enrolled into a phase II trial and were treated with temozolomide. The overall response rate was 33%. Further studies are needed to test the efficacy of temozolomide, alone or in combination in earlier stages of this disease.
منابع مشابه
Specific cutaneous manifestations in adult T cell leukemia/lymphoma
Background and aim: Adult T cell leukemia/lymphoma (ATLL) is an aggresive malignancy which may occur in human T lymphotropic virus1(HTLV1) infected persons. HTLV1 is endemic in Khorasan with prevalence of 2.3% in general population. Since specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied ATLL patients in Mashhad.Mate...
متن کاملGemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
BACKGROUND Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), the objective of the current study was to determine the role of gemcitabine in the treatment of patients with advanced, untreated CTCL. METHODS Between June 2002 and February 2004, 32 untreated patients with mycosis fungoides (MF) (n = 26 patients); peripheral T-cell lymphoma,...
متن کاملCutaneous lymphomas and pseudolymphomas: A ten-year study at Emam Reza and Omid hospitals in Mashhad, using immunohistochemical and new classification methods
Background: Cutaneous lymphomas are monoclonal neoplastic proliferations of immune cells most frequently T or B cells that infiltrates skin. Development of new diagnostic methods, particularly those for immunophenotyping, have substantially changed classification of these neoplasms. These reasons prompted us to perform this study. Objective: To re-classify cutaneous lymphomas and pseudoly...
متن کاملPhase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.
This phase 1/2 study evaluated the efficacy of mogamulizumab, a defucosylated, humanized, anti-CC chemokine receptor 4 monoclonal antibody, in 41 pretreated patients with cutaneous T-cell lymphoma. No dose-limiting toxicity was observed and the maximum tolerated dose was not reached in phase 1 after IV infusion of mogamulizumab (0.1, 0.3, and 1.0 mg/kg) once weekly for 4 weeks followed by a 2-w...
متن کاملPrimary cutaneous CD30+T cell lymphoma: A case report
Primary cutaneous CD30+ T cell lymphoma is rare lymphoma originally in and confined to the skin. These lymphomas usually present as a large solitary and often ulcerated nodule. Its prognosis is a good and has a good response to radiotherapy. We report a 34- year- old man who had primary cutaneous CD30+T cell lymphoma on his face, which presented as an ulcerated nodule.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Haematologica
دوره 90 9 شماره
صفحات -
تاریخ انتشار 2005